SI1272167T1 - Dozirna formulacija, ki vsebuje ropinirol, s hidrofilnim/lipofilnim polimernimm matriksom - Google Patents
Dozirna formulacija, ki vsebuje ropinirol, s hidrofilnim/lipofilnim polimernimm matriksomInfo
- Publication number
- SI1272167T1 SI1272167T1 SI200130871T SI200130871T SI1272167T1 SI 1272167 T1 SI1272167 T1 SI 1272167T1 SI 200130871 T SI200130871 T SI 200130871T SI 200130871 T SI200130871 T SI 200130871T SI 1272167 T1 SI1272167 T1 SI 1272167T1
- Authority
- SI
- Slovenia
- Prior art keywords
- liphilic
- ropinirole
- polymeric matrix
- dosage formulation
- containing hydrophilic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2000MI000852A IT1318470B1 (it) | 2000-04-14 | 2000-04-14 | Matrici polimeriche idrofile/lipofile, in grado di cedere sostanzefarmacologiamente attive a velocita' predeterminata. |
IT2000MI001963A IT1318687B1 (it) | 2000-09-07 | 2000-09-07 | Matrici polimeriche idrofile/lipofile, in grado di cedere sostanzefarmacologicamente attive a velocita' predeterminata. |
PCT/GB2001/001726 WO2001078688A1 (en) | 2000-04-14 | 2001-04-12 | Hydrophilic/lipophilic polymeric matrix dosage formulation |
EP01921605A EP1272167B1 (en) | 2000-04-14 | 2001-04-12 | Ropinirole-containing hydrophilic/liphilic polymeric matrix dosage formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1272167T1 true SI1272167T1 (sl) | 2008-12-31 |
Family
ID=26332740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200130871T SI1272167T1 (sl) | 2000-04-14 | 2001-04-12 | Dozirna formulacija, ki vsebuje ropinirol, s hidrofilnim/lipofilnim polimernimm matriksom |
Country Status (24)
Country | Link |
---|---|
US (4) | US20030180359A1 (sl) |
EP (4) | EP3175848A1 (sl) |
JP (2) | JP5073907B2 (sl) |
KR (4) | KR20080047630A (sl) |
CN (1) | CN1198598C (sl) |
AR (1) | AR030557A1 (sl) |
AT (1) | ATE401867T1 (sl) |
AU (3) | AU779623B2 (sl) |
BR (1) | BRPI0110038C1 (sl) |
CA (1) | CA2405508C (sl) |
CZ (1) | CZ303943B6 (sl) |
DE (1) | DE60134964D1 (sl) |
DK (1) | DK1272167T3 (sl) |
ES (2) | ES2580043T3 (sl) |
HK (1) | HK1053602A1 (sl) |
HU (1) | HU228269B1 (sl) |
IL (2) | IL152184A0 (sl) |
MX (1) | MXPA02010151A (sl) |
NO (1) | NO333572B1 (sl) |
NZ (1) | NZ521902A (sl) |
PL (1) | PL202689B1 (sl) |
PT (1) | PT1272167E (sl) |
SI (1) | SI1272167T1 (sl) |
WO (1) | WO2001078688A1 (sl) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
US7130822B1 (en) * | 2000-07-31 | 2006-10-31 | Cognos Incorporated | Budget planning |
GB0125088D0 (en) * | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
ITMI20020514A1 (it) * | 2002-03-12 | 2003-09-12 | Jagotec Ag | Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi |
BRPI0408323A (pt) * | 2003-03-14 | 2006-03-07 | Nirmal Mulye | processo para a preparação de compimidos de liberação prolongada |
EP1628642B2 (en) † | 2003-05-14 | 2013-01-23 | Aptalis Pharma Limited | Controlled drug release composition resistant to in vivo mechanic stress |
GB0319874D0 (en) * | 2003-08-22 | 2003-09-24 | Glaxo Group Ltd | Novel formulation |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US20060024368A1 (en) * | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
US20060068010A1 (en) * | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
US20060078621A1 (en) * | 2004-10-13 | 2006-04-13 | Wedinger Robert S | Method of providing customized drug delivery systems |
WO2006055928A2 (en) * | 2004-11-19 | 2006-05-26 | Smithkline Beecham Corporation | Pharmaceutical product |
US8022032B2 (en) | 2004-11-19 | 2011-09-20 | Smithkline Beecham Corporation | Method for customized dispensing of variable dose drug combination products for individualizing of therapies |
EP3228308A1 (en) | 2005-01-28 | 2017-10-11 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
TWI274889B (en) * | 2005-10-06 | 2007-03-01 | Elan Microelectronics Corp | Resistive touch screen measurement system |
US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
US20070185237A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
US7834066B2 (en) * | 2005-11-09 | 2010-11-16 | The Procter & Gamble Company | Denture adhesive articles |
US20070185232A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
US20070185233A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
US20100317763A1 (en) * | 2005-11-09 | 2010-12-16 | Jayanth Rajaiah | Denture Adhesive Articles |
US20070129460A1 (en) * | 2005-11-09 | 2007-06-07 | Jayanth Rajaiah | Denture adhesive articles |
US20090238776A1 (en) * | 2005-11-09 | 2009-09-24 | Arif Ali Baig | Oral Care Compositions and Methods |
US20070185236A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive compositions |
US20070185235A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive compositions |
FR2894143B1 (fr) * | 2005-12-01 | 2008-05-02 | Pierre Fabre Medicament Sa | Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation. |
KR100816064B1 (ko) * | 2006-08-16 | 2008-03-24 | 주식회사 케이티앤지 | 홍삼이 함유된 다중 정제 및 이의 제조방법 |
WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
MX2009002236A (es) * | 2006-08-30 | 2009-03-13 | Jagotec Ag | Formulaciones de dosis oral de liberacion controlada que comrpenden un nucleo y una o mas capas de barrera. |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
WO2008085484A2 (en) * | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
PL2187873T3 (pl) | 2007-08-13 | 2019-01-31 | Abuse Deterrent Pharmaceutical Llc | Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania |
KR101094231B1 (ko) * | 2008-02-18 | 2011-12-14 | 하나제약 주식회사 | 서방성 고형 제제 및 그의 제조방법 |
CN102131488A (zh) * | 2008-06-04 | 2011-07-20 | 宝洁公司 | 义齿粘合剂组合物和方法 |
SI22849A (sl) * | 2008-08-01 | 2010-02-26 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Ropinirolni pripravek |
WO2010015911A1 (en) * | 2008-08-06 | 2010-02-11 | Torrent Pharmaceuticals Limited | Sustained release pharmaceutical compositions of ropinirole and process for preparation thereof |
US20110195117A1 (en) * | 2008-09-01 | 2011-08-11 | Lupin Limited | Controlled release compositions of ropinirole |
PT2323633E (pt) * | 2008-09-04 | 2012-05-29 | Bristol Myers Squibb Co | Composição farmacêutica estável para a administração optimizada de um inibidor de união de hiv |
EP2163240A1 (en) | 2008-09-12 | 2010-03-17 | Universita' Degli Studi Di Genova | A method for the production of bioadhesive compact matrices |
CA2738414C (en) * | 2008-09-29 | 2014-05-27 | Wockhardt Research Centre | Extended release dosage form of ropinirole |
WO2010044108A2 (en) | 2008-10-17 | 2010-04-22 | Rubicon Research Private Limited | Controlled release formulations of ropinirole |
US20100233259A1 (en) * | 2008-12-12 | 2010-09-16 | Pascal Grenier | Dosage form of ropinirole |
US7927264B2 (en) * | 2009-07-24 | 2011-04-19 | Fitness Iq Llc | Low-impact inertial exercise device |
WO2011032416A1 (zh) * | 2009-09-19 | 2011-03-24 | 浙江华海药业股份有限公司 | 含有多巴胺受体激动剂的药物组合物 |
AU2011224350B2 (en) * | 2010-03-09 | 2015-07-02 | Alkermes Pharma Ireland Limited | Alcohol resistant enteric pharmaceutical compositions |
BR112012022646A2 (pt) | 2010-03-10 | 2016-08-23 | Procter & Gamble | composições adesivas para dentaduras |
CN103153334B (zh) * | 2010-10-15 | 2016-11-16 | 斯特劳曼控股公司 | 包含pga的新的emd制剂 |
GR1007629B (el) | 2011-07-13 | 2012-06-29 | Φαρματεν Αβεε, | Φαρμακευτικο σκευασμα ελεγχομενης αποδεσμευσης ενος μη εργολινικου αγωνιστη της ντοπαμινης |
EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
US11571390B2 (en) | 2013-03-15 | 2023-02-07 | Othemo Life Sciences, Inc. | Abuse deterrent compositions and methods of use |
EA201691454A1 (ru) * | 2014-01-22 | 2017-01-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Композиции придопидина модифицированного высвобождения |
MX2016015891A (es) | 2014-06-02 | 2017-07-11 | Teva Pharma | Forma de dosis gastrorretentiva expansible. |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
FR3026012B1 (fr) | 2014-09-23 | 2017-12-01 | Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic | Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
JP7071748B2 (ja) | 2016-12-02 | 2022-05-19 | クレキシオ バイオサイエンシーズ エルティーディー. | 胃内滞留システム |
JP7147262B2 (ja) * | 2017-05-23 | 2022-10-05 | 大正製薬株式会社 | 固形製剤 |
US11547839B2 (en) | 2017-12-04 | 2023-01-10 | Clexio Biosciences Ltd. | Long acting gastric residence system |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
JP7516738B2 (ja) * | 2018-11-06 | 2024-07-17 | 大正製薬株式会社 | 多層錠 |
KR102536511B1 (ko) * | 2020-06-25 | 2023-05-26 | (주) 넥스팜코리아 | 날트렉손 서방형 매트릭스 제제와 부프로피온 서방형 매트릭스 제제의 단층정 복합제제와 그 제조 방법 |
JP7098008B2 (ja) * | 2021-02-02 | 2022-07-08 | ライオン株式会社 | 積層錠剤及びその製造方法 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4452808A (en) | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
US4574082A (en) | 1983-07-29 | 1986-03-04 | Revlon, Inc. | One-phase silicone-based cosmetic products containing wax |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
IT1201136B (it) * | 1987-01-13 | 1989-01-27 | Resa Farma | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
GB8712073D0 (en) * | 1987-05-21 | 1987-06-24 | Smith Kline French Lab | Medicament |
GB8714371D0 (en) | 1987-06-19 | 1987-07-22 | Smith Kline French Lab | Process |
US5032406A (en) | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
FI900871A0 (fi) | 1989-02-24 | 1990-02-21 | Gist Brocades Nv | Patoeriseringsbestaendigt medel foer eliminering av syre. |
US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
JP2772695B2 (ja) | 1990-01-26 | 1998-07-02 | 日水製薬株式会社 | 3層錠 |
GB9008605D0 (en) | 1990-04-17 | 1990-06-13 | Smith Kline French Lab | Process |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
GB9015095D0 (en) | 1990-07-09 | 1990-08-29 | Smith Kline French Lab | Therapeutic method |
US5422121A (en) * | 1990-11-14 | 1995-06-06 | Rohm Gmbh | Oral dosage unit form |
JPH04360826A (ja) | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | 放出制御製剤 |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
US5186818A (en) | 1991-08-12 | 1993-02-16 | Exxon Research And Engineering Company | Catalytic processes |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5308729A (en) * | 1992-04-30 | 1994-05-03 | Lexmark International, Inc. | Electrophotographic liquid developer with charge director |
AU4312593A (en) | 1992-05-18 | 1993-12-13 | Smithkline Beecham Plc | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease |
IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
ATE184198T1 (de) | 1993-05-11 | 1999-09-15 | Spirig Ag | Festes bismut- und amoxycillinhaltiges arzneipräparat und seine verwendung |
IT1265074B1 (it) * | 1993-05-18 | 1996-10-30 | Istituto Biochimico Italiano | Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare |
IT1264517B1 (it) * | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
US5387110A (en) | 1993-11-12 | 1995-02-07 | International Business Machines Corporation | Reversible dual media adapter cable |
IT1265240B1 (it) | 1993-11-30 | 1996-10-31 | Ekita Investments Nv | Compressa farmaceutica a rilascio controllato, di forma lenticolare |
US5395626A (en) * | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
US5645858A (en) * | 1994-10-06 | 1997-07-08 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
GB9511366D0 (en) | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
GB9514842D0 (en) * | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
US5807570A (en) | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
IT1282576B1 (it) | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
DE19626045C2 (de) | 1996-06-28 | 1998-12-03 | Klinge Co Chem Pharm Fab | Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben |
US6623759B2 (en) * | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
JP3797388B2 (ja) * | 1996-08-29 | 2006-07-19 | サノフィ−アベンティス | アルフゾシン塩酸塩の放出制御錠剤 |
DE19640062B4 (de) * | 1996-09-28 | 2006-04-27 | Lts Lohmann Therapie-Systeme Ag | Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff |
IT1289160B1 (it) | 1997-01-08 | 1998-09-29 | Jagotec Ag | Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di |
EP0951279A1 (en) * | 1997-01-10 | 1999-10-27 | Abbott Laboratories | Tablet for the controlled release of active agents |
US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
FR2766708B1 (fr) * | 1997-07-30 | 2000-05-05 | Galenix Dev | Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
ES2229783T3 (es) | 1998-06-03 | 2005-04-16 | Alza Corporation | Dispositivos para proporcionar una terapia faramaceutica prolongada. |
US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
US6218421B1 (en) * | 1999-07-01 | 2001-04-17 | Smithkline Beecham P.L.C. | Method of promoting smoking cessation |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
US20030086972A1 (en) | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
JP4360826B2 (ja) | 2003-04-24 | 2009-11-11 | シャープ株式会社 | 半導体膜およびその製造方法 |
-
2001
- 2001-04-11 AR ARP010101750A patent/AR030557A1/es active IP Right Grant
- 2001-04-12 PL PL365837A patent/PL202689B1/pl unknown
- 2001-04-12 NZ NZ521902A patent/NZ521902A/en not_active IP Right Cessation
- 2001-04-12 US US10/257,709 patent/US20030180359A1/en not_active Abandoned
- 2001-04-12 IL IL15218401A patent/IL152184A0/xx unknown
- 2001-04-12 EP EP16192165.5A patent/EP3175848A1/en not_active Withdrawn
- 2001-04-12 ES ES06075502.2T patent/ES2580043T3/es not_active Expired - Lifetime
- 2001-04-12 AU AU48576/01A patent/AU779623B2/en not_active Expired
- 2001-04-12 JP JP2001575989A patent/JP5073907B2/ja not_active Expired - Lifetime
- 2001-04-12 CZ CZ20023415A patent/CZ303943B6/cs not_active IP Right Cessation
- 2001-04-12 EP EP01921605A patent/EP1272167B1/en not_active Expired - Lifetime
- 2001-04-12 MX MXPA02010151A patent/MXPA02010151A/es active IP Right Grant
- 2001-04-12 HU HU0300530A patent/HU228269B1/hu unknown
- 2001-04-12 SI SI200130871T patent/SI1272167T1/sl unknown
- 2001-04-12 KR KR1020087011476A patent/KR20080047630A/ko not_active Application Discontinuation
- 2001-04-12 BR BRPI0110038A patent/BRPI0110038C1/pt not_active IP Right Cessation
- 2001-04-12 CA CA2405508A patent/CA2405508C/en not_active Expired - Lifetime
- 2001-04-12 PT PT01921605T patent/PT1272167E/pt unknown
- 2001-04-12 CN CNB018091164A patent/CN1198598C/zh not_active Expired - Lifetime
- 2001-04-12 KR KR1020077013182A patent/KR20070065922A/ko active Application Filing
- 2001-04-12 ES ES01921605T patent/ES2307608T3/es not_active Expired - Lifetime
- 2001-04-12 EP EP06075502.2A patent/EP1681051B1/en not_active Expired - Lifetime
- 2001-04-12 AT AT01921605T patent/ATE401867T1/de active
- 2001-04-12 EP EP10176790A patent/EP2343060A1/en not_active Withdrawn
- 2001-04-12 DE DE60134964T patent/DE60134964D1/de not_active Expired - Lifetime
- 2001-04-12 KR KR1020097017509A patent/KR101158968B1/ko active IP Right Grant
- 2001-04-12 KR KR1020027013768A patent/KR100823392B1/ko active IP Right Review Request
- 2001-04-12 DK DK01921605T patent/DK1272167T3/da active
- 2001-04-12 WO PCT/GB2001/001726 patent/WO2001078688A1/en active IP Right Grant
-
2002
- 2002-10-08 IL IL152184A patent/IL152184A/en unknown
- 2002-10-11 NO NO20024919A patent/NO333572B1/no not_active IP Right Cessation
-
2003
- 2003-06-17 HK HK03104356A patent/HK1053602A1/xx not_active IP Right Cessation
-
2005
- 2005-04-29 AU AU2005201805A patent/AU2005201805B2/en not_active Expired
-
2007
- 2007-03-12 US US11/717,502 patent/US7927624B2/en not_active Expired - Fee Related
-
2008
- 2008-08-01 JP JP2008199847A patent/JP5420207B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-05 US US12/478,946 patent/US8303986B2/en not_active Expired - Lifetime
- 2009-10-26 AU AU2009230759A patent/AU2009230759A1/en not_active Abandoned
-
2011
- 2011-02-07 US US13/022,281 patent/US8460706B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1272167T1 (sl) | Dozirna formulacija, ki vsebuje ropinirol, s hidrofilnim/lipofilnim polimernimm matriksom | |
GB0104786D0 (en) | Active Matrix Device | |
EG23943A (en) | Flash-melt oral dosage formulation | |
GB0014074D0 (en) | Active matrix array devices | |
PL351526A1 (en) | Pharmaceutical formulation comprising amoxycillin | |
MXPA03006775A (es) | Formulacion farmaceutica. | |
AU6275601A (en) | Stable polymeric micelle-type drug composition and method for the preparation thereof | |
GB0031039D0 (en) | Active matrix devices | |
PL366067A1 (en) | Oxayolidinone tablet formulation | |
GB9909154D0 (en) | Pharmaceutical formulation | |
GB0014851D0 (en) | Novel pharmaceutical formulation | |
GB9926251D0 (en) | Pharmaceutical formulation | |
GB0014947D0 (en) | Novel pharmaceutical formulation | |
GB0014892D0 (en) | Novel pharmaceutical formulation | |
GB0014883D0 (en) | Novel pharmaceutical formulation | |
EP1414417A4 (en) | PHARMACEUTICAL FORMULATION | |
GB0014869D0 (en) | Novel pharmaceutical formulation | |
GB0019084D0 (en) | Pharmaceutical formulation | |
GB0018686D0 (en) | Pharmaceutical formulation | |
GB0018654D0 (en) | Pharmaceutical formulation | |
GB0014451D0 (en) | Pharmaceutical formulation | |
GB0014424D0 (en) | Pharmaceutical formulation | |
AU2001219899A1 (en) | Medicine ball | |
ZA200108250B (en) | Formulation arrays and use thereof. | |
GB0019840D0 (en) | Novel pharmaceutical formulation |